EPTIFIBATIDE

Eptifibatide received approval from the United States Food and Drug Administration (FDA) on May 17, 1998.

Eptifibatide is a medication primarily used to prevent blood clot formation in various medical situations. It is particularly used in cases where there is an increased risk of clotting, such as during certain cardiac procedures, acute coronary syndrome (ACS), and specific surgical interventions. It is also used for patients experiencing ACS, which includes conditions like unstable angina and non-ST segment elevation myocardial infarction (NSTEMI).

Eptifibatide is administered through intravenous (IV) infusion, which involves delivering the medication directly into the bloodstream through a vein using an IV line. This is typically done using specialized medical equipment, such as an IV pump, to control the rate of infusion. During the infusion, the patient's vital signs and overall response to the medication require close monitoring by the health care professional.

Eptifibatide may cause side effects, including an increased risk of bleeding, easy bruising, nausea, fever, headaches, and occasional dizziness.

Due to effect of Eptifibatide on platelets, it increases the risk of bleeding. Although rare, serious allergic reactions can occur. These might involve symptoms like rash, itching, swelling (especially of the face, lips, or throat), severe dizziness, and difficulty breathing. This medication might interact with other medications you're taking. Eptifibatide is cleared through the kidneys, so people having kidney diseases may get harmed.

If you have a history of bleeding disorders, recent surgeries, ulcers, or conditions that increase bleeding risk, caution is advised. Inform your healthcare provider immediately if you notice any signs of bleeding, such as unusual bruising, nosebleeds, or blood in your stool or urine. Individuals with a history of allergic reactions to eptifibatide or similar medications should exercise caution and inform their healthcare provider before starting treatment. If you have kidney problems, consult your your healthcare provider before starting this medication.

Inform your healthcare provider if you have a history of bleeding disorders, kidney disease, liver disease, or allergic reactions to medications. Notify your provider if you are scheduled for surgical procedures. Exercise caution with concurrent medications and limit alcohol consumption during treatment. Monitor for signs of bleeding, including unexplained bruising or haematuria. Ensure emergency medical personnel are aware you are taking this medication. Adhere strictly to the prescribed dosage regimen and maintain accessible emergency contact information. Seek guidance from your healthcare provider if you are pregnant, breastfeeding, or taking other medicines.

GlaxoSmithKline UK Limited,Electronic medicines compendium (EMC) [Revised on 21 May 2021] [Accessed on 18th Dec 2023], https://www.medicines.org.uk/emc/product/3889/smpc Kerstin Hogg and Jeffrey I. Weitz, Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs, Goodman and Gilman’s Pharmacological Basis of Therapeutics, 585-603 Merck & Co.Inc.US Food and Drug Administration, [Revised on 2nd 2021] [Accessed on 18th August 2023], / https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020718s039lbl.pdf